Winrevair slashes early PAH worsening by 76% in phase 3 Hyperion, but can it reset first-year care?

Merck & Co., Inc. (NYSE: MRK) has reported another milestone in its cardiovascular and rare disease portfolio, with the latest data on Winrevair (sotatercept-csrk) confirming its ability to slow pulmonary arterial hypertension progression in newly diagnosed patients. In the phase 3 Hyperion trial, Winrevair reduced the risk of clinical worsening events by 76 percent compared with placebo when given alongside standard background therapy. The findings were presented at the 2025 European Respiratory Society congress and published simultaneously in The New England Journal of Medicine, reinforcing the treatment’s clinical weight and its potential to redefine management practices in the critical first year after diagnosis.

For a disease as aggressive as pulmonary arterial hypertension, the first year often dictates the trajectory of long-term outcomes. Hyperion directly tested this early window, demonstrating how rapid initiation of Winrevair can provide durable protection even when patients are already on optimized dual or triple therapy. Analysts and institutional investors are now evaluating how quickly these results could be incorporated into global guidelines and what they might mean for Merck’s financial positioning in the cardio-pulmonary segment.

How did the phase 3 Hyperion trial of Winrevair demonstrate a 76 percent reduction in clinical worsening events for newly diagnosed PAH patients on background therapy?

The Hyperion trial enrolled patients who had been diagnosed with pulmonary arterial hypertension a median of seven months before study entry, reflecting the critical first-year risk period. These patients were predominantly intermediate to high risk, and more than 70 percent were already receiving double therapy with some on triple therapy. Participants were randomized to receive Winrevair or placebo in addition to their existing regimen.

The primary endpoint was a composite of all-cause death, unplanned hospitalizations of at least 24 hours, atrial septostomy, lung transplantation, or documented clinical worsening. Only 10.6 percent of Winrevair-treated patients experienced a first event, compared with 36.9 percent of placebo recipients. The hazard ratio of 0.24, with a 95 percent confidence interval between 0.14 and 0.41, translated into a 76 percent relative risk reduction. Kaplan–Meier curves diverged as early as week six and remained consistently separated, showing both the speed and the durability of the drug’s benefit.

Why do early initiation results from Hyperion matter for pulmonary arterial hypertension outcomes and how do they compare with previous trials like Stellar and Zenith?

Pulmonary arterial hypertension has historically been treated in a stepwise approach, where new therapies are added as disease worsens. Hyperion challenges this paradigm by showing that sotatercept’s vascular remodeling mechanism provides significant benefit when started earlier in the disease course and layered onto established therapy. This is particularly meaningful because the majority of clinical deterioration and hospitalization risk occurs within the first twelve months.

The results build on Merck’s earlier Stellar trial, which demonstrated improvements in functional measures such as six-minute walk distance and hemodynamics, and the Zenith trial, which confirmed mortality and morbidity reduction and was stopped early for overwhelming efficacy. Hyperion now completes this trilogy by proving efficacy in newly diagnosed patients, suggesting the benefit is not confined to later-stage populations. Analysts argue that the consistent effect across three pivotal trials makes a strong case for earlier use in routine practice and guideline updates.

What are the key safety findings from Hyperion and how do they align with Winrevair’s existing label precautions for patients with pulmonary arterial hypertension?

The safety profile in Hyperion was in line with prior trials and with Winrevair’s label. Adverse events were reported in 89.4 percent of patients on active treatment and 90 percent of those on placebo, while serious adverse events occurred in 24.4 percent and 28.1 percent respectively. The most common treatment-related events were headache, epistaxis, rash, telangiectasia, diarrhea, dizziness, and erythema.

Known risks such as erythrocytosis, thrombocytopenia, serious bleeding, embryo-fetal toxicity, and potential fertility issues were again highlighted. Clinicians stressed that appropriate monitoring of hemoglobin and platelet levels remains essential, particularly when Winrevair is used alongside prostacyclin or anticoagulation therapy. Importantly, no new safety signals emerged, reinforcing confidence that the drug can be managed safely in real-world practice with established monitoring protocols.

How did secondary endpoints such as multicomponent improvement and risk scores strengthen the case for Winrevair in newly diagnosed pulmonary arterial hypertension?

Secondary outcomes provided additional evidence that the clinical effect of Winrevair translates into broader patient benefit. By week 24, nearly 30 percent of patients in the active treatment arm achieved multicomponent improvement, defined as gains in six-minute walk distance, reductions in NT-proBNP biomarkers, and improvements in WHO functional class. Only 14.6 percent of placebo patients achieved the same.

Risk stratification outcomes further supported Winrevair’s profile. Sixty percent of patients receiving Winrevair maintained or achieved a low REVEAL Lite 2 score, compared with 47.9 percent of placebo patients. These scores are important because they are linked to long-term survival prospects. While not every secondary endpoint was met, such as shifts in the simplified French risk score, analysts noted that the statistical hierarchy used in the trial was deliberately conservative and did not detract from the primary efficacy message.

Why did Merck stop Hyperion early for benefit and how does this decision align with its broader strategy in pulmonary arterial hypertension trials?

The independent data monitoring committee recommended stopping Hyperion early after reviewing the overwhelming benefit. This was similar to the earlier Zenith trial, which also closed ahead of schedule for efficacy reasons.

The early stop reflects Merck’s broader strategy in pulmonary arterial hypertension: generate overlapping, confirmatory evidence that reduces regulatory uncertainty and accelerates label expansion. By halting the trial once equipoise was lost, Merck not only demonstrated ethical responsibility but also solidified its commercial and clinical case for earlier adoption of Winrevair.

How are regulators, payers, and guideline committees expected to interpret Hyperion’s results in the context of earlier initiation for intermediate-risk patients?

Regulators will view Hyperion as providing robust, statistically significant confirmation of Winrevair’s efficacy in an earlier disease stage. With approvals already secured in more than fifty countries on the back of the Stellar study, these data will likely support further submissions for label expansion emphasizing first-year initiation.

Payers will evaluate the economic trade-offs between drug cost and hospitalization avoidance. Since Hyperion showed a threefold difference in worsening events, many observers expect that health systems will recognize the downstream savings from fewer admissions and interventions such as transplant. Guideline committees in both Europe and the United States are anticipated to incorporate Hyperion’s data in upcoming updates, a move that could normalize earlier combination use across pulmonary hypertension treatment centers.

What does institutional sentiment around Merck’s stock suggest about Hyperion’s impact on growth prospects and the company’s cardiopulmonary franchise strategy?

Merck’s shares recently traded around USD 78.58. For investors, the key question is whether Winrevair can provide a sustainable growth bridge as oncology products approach patent cliffs later in the decade. Institutional sentiment appears cautiously optimistic, with many analysts noting that Hyperion lowers execution risk in the cardiopulmonary franchise and diversifies the company’s revenue base.

Investor outlook is generally neutral to positive, with “hold to accumulate” positions common across buy-side desks. The stock impact will depend on how quickly guidelines move, how payers respond, and how large the addressable patient base becomes if initiation shifts to the first year after diagnosis. For long-term holders, Hyperion strengthens confidence in Merck’s rare disease and cardiopulmonary growth engines.

Could Hyperion meaningfully expand Winrevair’s total addressable market by moving treatment initiation to the first year after pulmonary arterial hypertension diagnosis?

Hyperion’s design—focusing on patients within seven months of diagnosis already receiving dual or triple therapy—mirrors the real-world treatment landscape. By demonstrating large clinical benefit in this setting, Merck is positioned to argue for earlier initiation of Winrevair. If guidelines reflect this shift, the addressable market could expand substantially, with many more intermediate-risk patients qualifying earlier.

The pace of uptake will depend on the readiness of specialized centers to monitor patients, the willingness of payers to cover higher-cost regimens, and the durability of benefit in extension trials such as Soteria. Should these align, Hyperion could establish Winrevair as a first-year standard of care, transforming its commercial potential and changing the treatment trajectory for thousands of patients worldwide.

What Hyperion’s breakthrough means for Merck, investors, and the future of pulmonary arterial hypertension treatment?

Hyperion delivers one of the most compelling results seen in pulmonary arterial hypertension in years. A 76 percent reduction in clinical worsening events, achieved on top of optimized therapy and visible within six weeks, provides a strong case for earlier initiation of Winrevair. For Merck, it is the third pivotal trial confirming sotatercept’s benefit, cementing its cardiopulmonary franchise and offering investors a hedge against oncology headwinds.

For clinicians, the results challenge the “wait until worsening” paradigm and support proactive treatment within the first year of diagnosis. For patients, the message is clear: starting Winrevair early can reduce hospitalizations, lower the risk of invasive procedures, and improve survival prospects.